As TET2 function is dependent on the metabolites produced by the IDH proteins [21,32], susceptibility to STAT5 and MCL1 inhibitors may be similar in AML cells with IDH mutations, as in TET2 mutated cells. This evidence concerns the gene IDH2 and acute myeloid leukemia.